G. Bianchini

The role of the 21-gene assay in the neoadjuvant setting for hormone receptor-positive HER2-negative breast cancer: Impact on systemic and surgical treatment decisions

A.L. Guerrero Zotano, T.M. Allweis, R. Foerster, C. Palmieri et autres

In breast cancer, one of the main objectives of neoadjuvant treatment, regardless of the specific breast cancer subtype, is to downstage the disease in both the breast and the lymph nodes, thereby allowing surgical de-escalation. In patients with inoperable disease, downstaging could …

es, il, gb, ca, be, it (code pays fourni par la source)

Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial

M. Dugo, C-S Huang, D. Egle, B. Bermejo et autres

BACKGROUND: Triple-negative breast cancer (TNBC) is immunogenic, but only a subset of patients benefits from neoadjuvant immune checkpoint inhibitors combined with chemotherapy. Predictive biomarkers to guide patient selection and treatment adaptation are lacking. PATIENTS AND METHODS: In the randomized phase III NeoTRIPaPDL1 …

it, tw, at, es, us, de, ru, ie, hu, gb (code pays fourni par la source)

267P Real-world chemotherapy use in patients with high-risk hormone receptor–positive, HER2-negative (HR+/HER2-) early breast cancer treated with adjuvant abemaciclib

A. Chiavassa, A. Guarino, G. Viale, I. Persano et autres

The addition of 2-year abemaciclib to adjuvant endocrine therapy (ET) is a standard of care for patients (pts) with high-risk HR+/HER2− early breast cancer (eBC). In the monarchE trial, pts were unselected for genomic risk, and most (>95%) received (neo)adjuvant chemotherapy (CT) …

Correlation among pathological complete response (pCR), stromal tumor infiltrating lymphocytes (sTILs), and immune-related adverse events (irAEs) in early triple negative breast cancer (eTNBC) treated with neoadjuvant therapy

F. Patanè, A. Chiavassa, S. Zambelli, L. Licata et autres

it (code pays fourni par la source)

Targeting the future of axillary staging in node positive breast cancer patients receiving primary systemic therapy. A comparative study between axillary surgery and [18F]-FDG PET/MRI

R. Di Micco, E. Botteri, C. Canevari, Francesca Gallivanone et autres

it, no (code pays fourni par la source)

Abstract PS3-09-18: Early AB-ITALY: Evaluating Real-World Use of Adjuvant Abemaciclib and Drug Interaction Risk in HR+/HER2- early Breast Cancer

Simone Scagnoli, M. Verrico, Simona Pisegna, R. Caputo et autres

Abstract Introduction Abemaciclib is a selective CDK4/6 inhibitor approved for adjuvant treatment in patients with high-risk hormone receptor-positive, HER2-negative (HR+/HER2-) early breast cancer (eBC). The MONARCH-E trial demonstrated significant increase in invasive disease-free survival (iDFS) when combined abemaciclib with endocrine therapy. Nonetheless, …

it, us, be, lb, de (code pays fourni par la source)

Abstract PS5-01-27: Outcomes by hormone receptor (HR) status in patients (pts) with HER2+ advanced/metastatic breast cancer (mBC) with brain metastases (BM) treated with trastuzumab deruxtecan (T-DXd): a post-hoc subgroup analysis of DESTINY-Breast12

H. Wildiers, N. Harbeck, E. Ciruelos, Guy Jérusalem et autres

Abstract Background: T-DXd demonstrated substantial and durable overall and intracranial clinical activity in DESTINY-Breast12. In pts with BM, 12-month progression-free survival (PFS) and central nervous system (CNS) PFS rates were 61.6% and 58.9%, respectively, and CNS objective response rate (ORR) was 71.7% …

be, de, es, jp, it, at, ch, ie, au, fr, sg, nl, us (code pays fourni par la source)

Abstract PS5-08-19: Randomized phase 3 trial evaluating KAT6 inhibitor PF-07248144 plus fulvestrant in HR+HER2− advanced/metastatic breast cancer after progression on CDK4/6 inhibitor-based therapy

K. M. Kalinsky, R.M. Layman, A. Giordano, T. Mukohara et autres

Abstract Background: Patients with HR+HER2− advanced/metastatic breast cancer (ABC) who have tumors that progressed after CDK4/6 inhibitor and endocrine therapy (ET) represent a high unmet medical need. Histone lysine acetyltransferases KAT6A and KAT6B regulate lineage-specific gene transcription via H3K23 acetylation. PF-07248144 is …

us, jp, kr, au, it, fr, de, cn, es (code pays fourni par la source)

Abstract PD10-04: Visual functioning and characterization of visual effects from SERENA-6, a Phase 3 study of switch to camizestrant (CAMI) from aromatase inhibitor (AI) while continuing CDK4/6 inhibitor (CDK4/6i) at emergence of ESR1 mutations (ESR1m) during first-line therapy for patients (pts) with HR+/HER2− advanced breast cancer (ABC)

Adam Brufsky, F. C. Bidard, EL Mayer, Y. H. Park et autres

Abstract Background In SERENA-6, switching to CAMI from AI while continuing CDK4/6i at emergence of ESR1m during first-line therapy in pts with HR+/HER2− ABC significantly improved PFS, was well tolerated, and reduced the risk of deterioration in quality of life vs AI …

us, fr, kr, de, it, jp, pl, es, tw, il, kh, tr, ag, gb, sg (code pays fourni par la source)

Abstract RF7-03: Updated results and an exploratory analysis of ESR1m circulating tumor DNA (ctDNA) dynamics from SERENA-6, a phase 3 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1 mutations (ESR1m) during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2- advanced breast cancer (ABC)

F. C. Bidard, EL Mayer, Y. H. Park, W. Janni et autres

Abstract Background: At SERENA-6 interim analysis, switching to CAMI, with continued CDK4/6i, at ESR1m emergence during 1L aromatase inhibitor (AI) + CDK4/6i significantly improved PFS, extending time on first-line therapy, and delayed time to deterioration (TTD) in global health status and quality …

fr, us, kr, de, it, jp, ca, pl, es, il, tw, Éthiopie, pr, sg, nl, gb (code pays fourni par la source)

Abstract PS5-04-18: Real-world patterns of trastuzumab deruxtecan discontinuation in metastatic breast cancer: insights from a single-center experience

Luca Licata, G. Viale, Francesca Patanè, Antonella Chiavassa et autres

Abstract Background Trastuzumab deruxtecan (T-DXd) is an approved standard-of-care treatment for patients (pts) with both HER2-positive (HER2+) and HER2-low, previously treated metastatic breast cancer (MBC). Clinical trials have shown that a substantial proportion of pts (approximately 30–50%) discontinue treatment for reasons other …

it (code pays fourni par la source)

Abstract PS1-01-13: Examining Antiemetic Management with Antibody-Drug Conjugates (ADCs) in Patients with Breast Cancer: Healthcare Provider (HCP) Insights from a SABCS Survey

Lee S. Schwartzberg, Luca Licata, G. Bianchini, Y. H. Park et autres

Abstract Background: Antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) have revolutionized breast cancer (BC) treatment, providing superior efficacy that allows for extended treatment durations. Nausea and vomiting (NV) are among the most frequent adverse effects associated with …

us, it, kr, jp, fr, de, ch (code pays fourni par la source)